
NASDAQ:CLBT
This summary was created by AI, based on 3 opinions in the last 12 months.
Cellebrite (CLBT) continues to attract positive sentiment among analysts, who express a preference for awaiting the upcoming earnings report scheduled for November 12. This strategic approach reflects a common practice among investors to gather more comprehensive insights before making investment decisions. Experts like Trevor Rose emphasize the importance of current information, indicating a cautious but optimistic outlook on the stock leading up to earnings. The company is poised for further consideration, as its market position suggests potential benefits depending on the forthcoming financial performance. Overall, there appears to be a consistent belief in the company's prospects, although a wait-and-see attitude prevails until more data is available.
We continue to like CLBT. The company reports Nov. 12 so in the least, we would prefer to wait for earnings and make a decision thereafter with more up to date info.
Unlock Premium - Try 5i Free
We continue to like CLBT. The company reports Nov. 12 so in the least, we would prefer to wait for earnings and make a decision thereafter with more up to date info.
Unlock Premium - Try 5i Free
Its performance has been disappointing, and we do look at momentum of stocks (negative here). But we still think it is worth holding for mid-cap growth investors. It has $500M cash, and good earnings growth is expected still, and the sector outlook overall remains robust.
Unlock Premium - Try 5i Free
It is very good at tracing data for the police, military and other agencies. One of the best use cases for AI is looking at data. This is so good for the overwhelming amount of info that police have to look at. CLBT scrubs the info to find clues and patterns and can find information quickly. It has $400 million in cash along with very good growth. With a market cap of less than $4 billion it is much smaller than other companies in the same field. The customer base gives confidence in the company. Buy 8 Hold 0 Sell 0
(Analysts’ price target is $22.43)Cellebrite is a American stock, trading under the symbol CLBT (previously CLBT-Q on Stockchase) on the NASDAQ (CLBT). It is usually referred to as NASDAQ:CLBT or CLBT
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on CLBT (previously CLBT-Q on Stockchase). 0 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is HOLD. Read the latest stock experts' ratings for Cellebrite.
Cellebrite was recommended as a Top Pick by Stockchase Insights on 2025-11-10. Read the latest stock experts ratings for Cellebrite.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Cellebrite.
Cellebrite is followed by 9 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-16, Cellebrite (CLBT) stock closed at a price of $15.83.
We continue to like CLBT. The company reports Nov. 12 so in the least, we would prefer to wait for earnings and make a decision thereafter with more up to date info.
Unlock Premium - Try 5i Free